Releaf

Releaf

Retail

London, London 3,012 followers

The only all-in-one medical cannabis subscription, transforming how patients acquire and experience medicinal cannabis.

About us

Releaf, founded in 2022, is a healthcare company dedicated to transforming patient access to Cannabis Based Products for Medical use (CBPMs) in the UK. Despite the legalisation of medical cannabis in 2019, its uptake has been limited. An estimated 1.8 million people in the UK rely on illicit street cannabis for medical purposes, while over 20 million adults could benefit from CBPMs but are unaware of their options. Currently, only around 30,000 people in the UK have an active CBPM prescription. The primary obstacles to broader adoption are the complexity of the prescribing process and a lack of awareness among medical professionals and potential patients. Releaf has made significant investments in developing a HealthTech platform to streamline access to CBPMs for patients with various health conditions. The platform was launched in February 2024, eliminating previous barriers and bringing about fundamental changes in the UK's CBPM sector. Our Leadership Team has a proven track record in navigating complex, regulated markets. Through substantial investments in time, money, and expertise, we have developed Releaf's HealthTech operating platform. This platform simplifies the intricate and makes the opaque transparent, ensuring a seamless, single online session for patients to access CBPMs for their relevant conditions. Press enquiries: Press@releaf.co.uk

Website
https://releaf.co.uk/
Industry
Retail
Company size
11-50 employees
Headquarters
London, London
Type
Privately Held
Founded
2022
Specialties
Medical Cannabis, Medicinal Cannabis, Health and Wellness, Consumer Healthcare, Healthcare, Subscription Business, Direct to Consumer, Technology, and Healthtech

Locations

Employees at Releaf

Updates

  • Charlotte, we’ve loved reading your “I Had a Dream Series” and have found a valuable opportunity in it by responding to each instalment to demonstrate how Releaf is putting patients first - as you have noted! At Releaf, we’re proud to lead the moment towards a brighter future in the UK's #medicalcannabis sector. - We remain committed to providing data-driven insights and transparent communication to empower patients and specialists alike. - Breaking down barriers to ensure patients can access high-quality care and treatment is central to our mission. A seamless, supportive patient journey is what we strive to deliver every day - amplified by our proprietary HealthTech platform, excellent Clinical Team of 26+ doctors and on-demand Patient Support Team. - Through vertically integrated solutions (thanks to our strategic partners including Glass Pharms and SOMAÍ Pharmaceuticals) advanced patient outcome tracking with our PROs and specialist consultants who have received the highest-standard of training - Releaf is setting new benchmarks for consistency and excellence in the industry. Your series has provided inspiration and focus for the changes we all want to see in the sector for 2025. Our priority will always be to drive for a #patientfirst industry. Wishing you a wonderful holiday season! #Releaf #MedicalCannabisUK #PatientCare

    View profile for Charlotte Caldwell, graphic

    Mother of Billy , the little boy who changed the UK Medical Cannabis Law.

    Santa’s Wish List: A Dreamy Recap of “I Had A Dream Series - UK Prescription Cannabis” Huddle up, holiday elves! It’s time to sleigh through a recap of my “I Had a Dream Series”2024 and unwrap our wish list for a magical 2025! Think mistletoe, myths, and merry solutions, all wrapped in a bow. Let’s unwrap this festive dream, one at a time. Misinformation Mania: The Ghost of Myths Past Forget the holiday rumors, prescription cannabis isn’t a miracle cure-all. Trust data, not Santa-sized hearsay! We’re sleighing the falsehoods with cold, hard facts. The Growth That Got Grinched The cannabis industry’s potential is as bright as Christmas lights… but bureaucracy is playing Scrooge. Red tape, financial frosts, and expertise in short supply? Misleading Moves: Who’s on the Naughty List Dodgy lobbying, poor quality, and unreliable healthcare service coupled with subpar supply have been stuffing the industry’s stocking with coal. It’s time for industry to tidy up this chimney of chaos. Patient Choice: Frostbitten Dreams A prescription isn’t much of a gift when patients can’t actually access their meds. The gap needs fixing faster than Santa’s sleigh on Christmas Eve. Consistency is King: Clinics to the Rescue The elves of the cannabis world? Vertically integrated clinics - Releaf Glass Pharms their ensuring quality, streamlining care, and delivering solutions that sparkle brighter than a star on the tree. Tracking Triumphs: Data to the Rescue Like Rudolph’s nose lighting the way, clinics tracking patient outcomes are guiding the industry to evidence-based care. Proof beats hype, every time. Accessibility Elevated: All Aboard the Sleigh From consultation to treatment, the best clinics are decking the halls with patient-first systems. True accessibility isn’t just about getting there - it’s about getting better. Specialised Consultants: Industry MVPs Move over, Santa! Specialist medical cannabis consultants are the true legends. They’re crafting tailored care that’s the ultimate gift for patients. Unbiased Forums: Safe Spaces, Please! Patients need places to share stories without all the tinsel and spin. Honest, open forums? Cannabis niave patients cosy! Consider it another of our Christmas wish’s. Regulations Gone Rogue: Naughty Rules The UK’s regulations are more tangled than Christmas lights- giving some industry elves the perfect “get out Claus” to avoid following the rules. Let’s dream of a world where these naughty elves move onto Santa’s nice list! Dreams may be the twinkling lights, but let action be the shining star! Together, let’s light the way to a joyful and brighter future for prescription cannabis in 2025. Wishing you all the sparkle, cheer, and magic this Christmas and may all your holiday wishes sleigh their way into reality in 2025!

    • No alternative text description for this image
  • 'Releaf’s domination of the sector is now a matter of record, not opinion.' Our CEO, Tim Kirby sat down with Business of Cannabis | Europe to discuss our proprietary HealthTech platform. Our £2M platform, is designed to drive high-performance behaviours through real-time data insights. Tim comments; 'As a result of using data-backed insights to drive high-performance behaviours, our patient outcomes are exceptional - as is patient engagement and advocacy.' This approach has quickly led to us becoming the fastest-growing and most trusted #medicalcannabis provider in the UK, according to Trustpilot. Just take a look at our reviews to see Releaf patients' quality of life improvements - they speak for themselves! Have a look at our platform and discover more of our innovative tech including V2 of our Patient Portal, here: https://lnkd.in/ddnbXmt4

    Releaf HealthTech is reshaping the #UK’s medical cannabis sector by focusing on behaviours over results. Speaking to Business of Cannabis, CEO Tim Kirby explained that their proprietary HealthTech platform—developed with a £2M pre-revenue investment—was designed to drive high-performance behaviours through real-time data insights. This approach has made Releaf the fastest-growing and most trusted medical cannabis provider in the UK, with the highest Trustpilot ratings and patient advocacy in the sector. Releaf’s focus on patient outcomes and experience is evident in innovations like their newly launched Patient Portal V2. Kirby stressed that success isn’t about chasing results but understanding and replicating the behaviours that deliver exceptional patient care. Read the full story here: https://lnkd.in/ddnbXmt4 #CannabisNews #HealthTech #PatientCare

    • No alternative text description for this image
  • At Releaf, we have dedicated ourselves to providing a patient-first approach that tackles many of the problems you’ve outlined Charlotte Caldwell As one of our patients mentioned mentioned in a recent 5* Trustpilot review; 'it really feels like providing you [with] support is their primary objective.' Here’s how Releaf is making a difference: Accessible Expertise: We are committed to employing only the highest-trained specialists to consult patients who are knowledgeable, confident, and compassionate in their approach. On top of the detailed onboarding and training programme required upon joining Releaf, we ensure they receive continuous training throughout their Releaf journey. Quality Assurance: Every medication that Releaf provides meets stringent standards - reflected in strategic partnerships including with Glass Pharms, the UK's first domestic CBPM; to go that one step further, we guarantee the quality of medication through our Patient Charter, as well as its timely and consistent supply, with prescriptions delivered direct to patients' doors within 2-4 working days. Affordability and Transparency: We offer clear pricing, with no hidden fees and a subscription plan, Releaf+, that keeps costs to a minimum with all consultations, dispensing and postage fees included for £39.99/month. Simplifying the Process: By offering a seamless consultation and prescription experience in-house with our proprietary HealthTech platform, we minimise red tape for our patients. Our Patient Support Team is also always on demand to help guide patients through the process if they need assistance. At Releaf, we believe that access to #medicalcannabis shouldn’t be a privilege - all patients should have the power and confidence to be in control of their health. #patientcare will always be our priority!

    View profile for Charlotte Caldwell, graphic

    Mother of Billy , the little boy who changed the UK Medical Cannabis Law.

    Welcome to final installment - I Had A Dream Series: Regulatory Challenges: How UK Prescription Cannabis regulations have impacted patient care Since its much celebrated legalisation in 2018, the prescription cannabis scene in the UK has been like a promising new show bogged down by terrible reviews, thanks to the star performers: regulatory hurdles and some of the industries bad practices. What was meant to be a game-changer for patient care has turned into a bureaucratic obstacle course assisted by some companies providing dodgy healthcare leaving patients and doctors scrambling for solutions. Let’s talk Schedule 2 drugs. This classification under the Misuse of Drugs Regulations 2001 sounds official and it is, but here’s the kicker: while cannabis-based medicines can be prescribed, only specialists get the golden ticket to do so. General practitioners? Nope, they’re benched. Specialists, meanwhile, are often untrained, half-trained, nervous, or both. The result? Long waits, frustrated patients, and a system that moves slower than a snail on sedatives. Then there’s NICE (that’s the National Institute for Health and Care Excellence, ironically). NICE has greenlit cannabis-based medicines, but only for a tiny selection of conditions. Rare epilepsies, multiple sclerosis, and chemo-induced nausea. Chronic pain? NHS access ? Forget about it. This leaves a whole host of patients stuck in the no-hope-for-you line, while other countries have already embraced prescription cannabis as a go-to option for pain relief. Even for those who do qualify, there’s another plot twist: finding quality medicine. Licensed cannabis products are as rare as sunshine in a British winter. Patients dive into their own pockets to pay privately, opening the door for certain, but not all providers to offer imported meds that might come with a side of mold, a sprinkle of insects, a dash of seeds, or other funky surprises. Recipe for some serious head scratching over the quality and safety standards in some of these private clinics. MHRA- dreaming of a white Christmas? To make things worse, healthcare professionals are flying blind. Training? Minimal. Clear guidelines? Conveniently ignored. Confidence in prescribing? Questionable in some practices. The result? A vicious cycle of uncertainty that keeps patients waiting, doctors hesitating, and cannabis gathering dust in a bureaucratic limbo. This tangled web of red tape, meant to ensure safety, has morphed into a straitjacket for patient care. If the UK wants to unlock the real potential of Prescription Cannabis it’s time to cut the red tape, broaden the guidelines, educate clinicians better. Some industry players need to wrap it up like a perfect Christmas present and stop behaving like they’re running Santa’s candy shop! Until then, patients will remain stuck in this regulatory maze exploited by the “Grinch” who just took all your Christmas Amazon packages.

    • No alternative text description for this image
  • We couldn’t agree more about the need for unbiased, judgment-free platforms in the #medicalcannabis space to both empower patients and educate a wider community about the sector. That’s why we’re working to amplify patient voices through initiatives like our Patient Stories, where individuals can share their experiences to help others navigate their own journeys. https://lnkd.in/gzM346ke Our Trustpilot reviews speak for themselves, 600+, (a greater volume than that of providers who have been active since legalisation six years ago in 2018) and the highest number of 5-star ratings, in which patients share deeply personal and often moving accounts of the quality of life improvements they’ve experienced since starting their Releaf treatment plan. To take that one step further at Releaf, we’ve embedded condition-specific questionnaires designed to gather research-backed data. These insights will allow us to better understand patient outcomes and contribute to the evidence base for CBPMs - because real stories and real data go hand in hand. We’re proud to support and lead the creation of safe, judgment-free spaces for everyone involved. Together, we can move the conversation forward and ensure no one lacks knowledge or support throughout their treatment plan. #DataDrivenCare #PatientCare

    View profile for Charlotte Caldwell, graphic

    Mother of Billy , the little boy who changed the UK Medical Cannabis Law.

    Welcome to my I Had A Dream Series: Installment 10 - Open Forums on Prescription Cannabis: The need for unbiased patient platforms. Let’s face it Prescription Cannabis is going mainstream, and the buzz (pun totally intended) is real. Countries are loosening up, research is booming, and laws are catching up. But here’s the kicker: there’s a lack of unbiased forums for patients to swap stories, ask burning questions, and get the tea on what actually works. Yep, we’re talking open, no-judgment zones for the cannabis-naive and the medically motivated. Why Do We Care? Because Open Forums Are a Big Deal For some folks, prescription cannabis is the last Hail Mary when other meds just don’t cut it. But instead of clarity, they get drowned in half-baked info and stigma leftovers. That’s why open forums need to exist. Safe judgment-free zones where even the most cannabis-naïve can ask, “What’s a tincture, and why does everyone talk about high THC flowers like they’re the “final boss?” These forums can also bridge the gap between lab coats and real-life users. Clinical trials are great and all, but they often miss the juicy details: the weird side effects, surprising benefits, and that time someone’s grandma administered an edible and became couch locked. Real talk = real insights. Unbiased or Busted: The Real Deal with Open Platforms Here’s the catch: forums can easily go from real medical stories to infomercial nightmares! The cannabis industry is growing faster than the tech boom of the 2000’s and some companies can’t resist sneaking in to push their products. An unbiased forum? It’s like the Holy Grail - focused on patients, not profits. Plus, let’s get some actual experts in the room. Think myth-busting moderators who know the difference between THC and “that stuff my cousin swears cured his dog’s arthritis.” It’s about serving facts, not fluff. So, What’s Next? The Game Plan If we’re going to do this right, we need a squad: patients, docs, researchers and advocates in the same forum all working together. Non-profits and government backing wouldn’t hurt either. Think Kickstarter, but for knowledge-sharing. The endgame? A world where talking about prescription cannabis feels as normal as asking your local cafe for oat milk. Open, unbiased forums could smash stigma, level up patient care, and finally answer the question, “Is it normal to feel my anxiety escalate after one dose?” Prescription Cannabis patients need safe spaces to chat without judgment and recreational users gate crashing! Like in a book club - just to talk about movie adaptations, for them it’s fun! Disruptive and confusing for those who came for the actual chapters. Let’s make it happen, one real medical , unbiased platform at a time. We’ve kicked things off - now it’s your turn to jump in and join us. Billy & Charlotte x https://lnkd.in/dykS7ckB

    B.CBD on Prescription | Facebook

    B.CBD on Prescription | Facebook

    facebook.com

  • Our CEO, Tim Kirby sat down with SOMAÍ Pharmaceuticals CEO, Michael Sassano to discuss the future of the medical cannabis sector, in particular, how our strategic partnership is helping to generate exceptional patient outcomes in the UK. 70% of our patients are cannabis naive and some can be uncomfortable with flower and vaporising; that's why, with the help of SOMAÍ Pharmaceuticals we're working to open new demographics. SOMAÍ’s oils have been rigorously tested in independent studies and are regarded among the best in the world, with a purity and consistency comparable to that of extra virgin olive oil. This dedication to quality is sown in the clarity and consistency of their oils: Our partnership with SOMAÍ means that our patients will always benefit from treatment plans of guaranteed quality and consistency, which is why we have not only the most evolved and reliable supply chain in the UK market, but also why we are also the most trusted CBPM clinic in the UK. #patientcare #medicalcannabis #podcast Listen now: Youtube 📹 👉 https://lnkd.in/eNgimFNw Spotify 🎧 👉 https://lnkd.in/e_kpzum9

    View organization page for Business of Cannabis, graphic

    9,779 followers

    Business of Cannabis: Podcast | Releaf x SOMAÍ Pharmaceuticals 🎙 Next up we have a special episode with Tim Kirby, Chief Executive Officer with Releaf and Michael Sassano, CEO and Chairman of the Board with SOMAÍ Pharmaceuticals. Join us as our Business of Cannabis guests discuss the highs and lows of the industry from the United States to Europe, they share the skills required to navigate the cannabis market, and how they hope the future of cannabis will take shape over the next few years. Youtube 📹 👉 https://lnkd.in/eYRbGEfW Spotify 🎧 👉 https://lnkd.in/dA_nprKG #podcast #cannabispodcast #cannabisindustry

  • At Releaf, we see first-hand how personalised, expert guidance transforms patient outcomes in the #medicalcannabis sector. Specialised consultants don’t just guide treatments; they build bridges between complex #science and real-world application, ensuring patients feel confident and supported every step of the way. Led by our COO, Graham Woodward, Releaf’s Clinical Team receive comprehensive #training and participate in #onboarding programmes upon joining. Graham commented in a recent interview with Business of Cannabis | Europe: 'We have a mix of about 26 doctors on our team, including some of the most experienced cannabis prescribers in the country, as well as newer doctors just beginning their journey with cannabis prescribing. It’s critical to have people who are genuinely interested in learning—not just about cannabis, but about the conditions it can treat.' The dedication of our specialists to ongoing monitoring and individualised care is crucial in helping patients thrive, not just managing symptoms. We’re proud to play our part by providing tools and data that empower both patients and clinicians to make informed decisions; from our training programmes to our PROs (patient reported outcomes), a research project led by our Dr Hanna Gul, in which a comprehensive arrangement of questionnaires will sit within Releaf’s proprietary HealthTech platform to capture valuable insights into patient experiences, treatment efficacy, and overall outcomes. This data-driven approach not only enhances personalised care but also contributes to the broader understanding of medical cannabis therapy, supporting clinicians in refining their practices and improving patient well-being. With the right tools, training, and insights, we can transform lives and help unlock the full potential of medical cannabis for patients in need around the UK.

    View profile for Charlotte Caldwell, graphic

    Mother of Billy , the little boy who changed the UK Medical Cannabis Law.

    Welcome to I Had a Dream Series Installment 9 - Value in Care: Why Specialised Consultants Are the MVPs of Medical Cannabis The world of medical cannabis is blossoming faster than a spring garden, offering solutions for a variety of health conditions. But let’s face it, using cannabis as medicine isn’t as simple as picking up a pre-roll. Enter the heroes of the story: specialised doctor consultants. These experts are the GPS for patients navigating the winding roads of cannabis therapy. Experts in Building the Perfect Medical Cannabis Plan One size definitely doesn’t fit all, especially in medicine. Specialised consultants are like personal trainers for your health. They dig into your medical history, symptoms, and treatment responses to craft a plan that’s just right for you. From choosing the right strain to nailing the perfect dosage, they ensure your cannabis journey is safe, effective, and totally personalised. Cracking the Medical Cannabis Code Cannabis isn’t just one plant - it’s a chemistry set full of cannabinoids, terpenes, and delivery options. Trying to figure it out solo? That’s like solving a Rubik’s cube blindfolded. These consultants geek out over the science so you don’t have to, turning complex pharmacology into clear, actionable steps for your treatment. Safety First, Always The legal and regulatory world of medical cannabis is, let’s be honest, a bit of a maze. Specialised consultants are your compliance coaches, guiding you through local laws, protocols, and potential pitfalls. They don’t just set you up and wish you luck - they stick around, monitoring your progress and tweaking treatments to keep you on the safest, most effective path. Medical Cannabis School: Empowering Patients Knowledge is power, and these consultants are all about sharing the wealth. They break down the pros, cons, and everything in between so you can make informed decisions about your health. With their guidance, you’re not just a patient, you’re an empowered partner in your care. A Blend of Old and New Think of these specialists as medical mixologists, blending the best of traditional treatments with cutting-edge prescription cannabis therapies. They focus on holistic healing, putting your overall well-being front and center. It’s not just about symptom relief; it’s about thriving long-term. Medical cannabis is brimming with potential, but it needs expert pilots to chart the course. With specialised consultants leading the way, patients can embrace this therapeutic frontier with confidence, clarity, and a touch of quirkiness.

    • No alternative text description for this image
  • We are delighted to announce an extension to our exclusive supply agreement with Los-Angeles based heat not burn technology company – Omura . At Releaf, we put patients first in every decision, from our team, to the medication and products we offer. While #medicalcannabis has been legal in the UK since 2018, strict regulations govern its use. Due to health risks associated with combustion, smoking cannabis - even for medical purposes - remains illegal. This means flower patients must consume their prescription via a vaporiser. Omura shares our commitment to exceptional patient outcomes, directly addressing concerns tied to traditional vaporisers. Together, we’re focused on creating a superior, controlled experience for Releaf patients. Why we chose Omura: Dose-Controlled Experience: Omura’s Flowerstick System offers patients a consistent 0.12g dose of cannabis flower per stick, ensuring precise dosing and ensuring patients are in control of their experience. Proprietary Heat-Not-Burn Technology: Omura’s heat-not-burn technology optimises vaporisation, enhances the Entourage Effect, and ensures 99% cannabinoid extraction. By heating cannabis over a controlled range, the device avoids combustion, preserving the integrity of cannabinoids and terpenes. This technology delivers a smoother, more flavourful vapour and maximises therapeutic benefits. Ease of Use: Designed for simplicity, Omura’s device requires no packing, cleaning, or handling of sticky concentrates. Users simply insert a flowerstick and inhale, making it ideal for those new to cannabis or with limited dexterity. Portability: Omura’s compact, lightweight vaporiser fits conveniently into a pocket or bag, supporting patients’ daily routines with a long-lasting battery, ideal for on-the-go use without constant recharging. Discretion: Omura’s sleek, modern design emits minimal vapour and odour, making it the most discreet option for patients medicating in public or shared spaces. Its high-tech appearance resembles a gadget rather than a medical device. Sustainability: Omura is environmentally conscious; their flowersticks are made from FSC-certified pulp, making them sustainable and biodegradable—an eco-friendly choice over plastic-heavy alternatives. Our partnership with Omura underscores our commitment to providing the highest standard of care. By exclusively offering Omura’s products, we empower patients with safe, precise, and consistent ways to manage their treatment plans and experience the full therapeutic potential of medical cannabis. This collaboration aligns with our core mission of prioritising patient outcomes through innovative, patient-centred solutions, giving patients control of their health with the transformative benefits of medical cannabis. #patientcare #innovation

    • No alternative text description for this image
  • Our very own Rupa Shah and Graham Woodward had an insightful conversation with Business of Cannabis | Europe last week to talk about best practices for #compliance in the UK's #medicalcannabis sector. Our exceptional leadership team, including Rupa and Graham, have a stellar track record of leading rapid growth in complex, highly-regulated sectors. Meaning Releaf is able to expertly handle a difficult challenge: going to market in a fully compliant manner; a task that is not easy in this industry. 'Compliance is integrated into every part of our culture. [...] Everyone - whether in marketing, patient support, or any other team - understands that compliance is critical for gaining the trust of our patients.' This ethos is what drives our success and is what sets us part to lead the UK's #medicalcannabis sector. By embedding compliance into every aspect of our operations, both internal and external, we ensure that we are delivering the highest standards of care and trust to our patients. Thank you Business of Cannabis | Europe for hosting this discussion; it's through conversations like these that Releaf continues to raise the bar for #compliance and patient-focused innovation in the industry.

    Releaf Clinic's compliance lead, Rupa Shah, and operational training expert, Graham Woodward RNMH FCMI, shared how the company seamlessly integrates CAP Code adherence and ASA regulations with a patient-first approach. They emphasise that compliance is embedded into the company culture from onboarding to daily operations, fostering trust and transparency. Releaf also tackles stigma through clinician education, offering evidence-based resources and free training for healthcare professionals starting in 2025. By equipping their team and external clinicians with the tools to navigate this complex sector, Releaf aims to raise industry standards and reduce misconceptions about cannabis-based medicines. Read here: https://lnkd.in/dV-dPnrB 👉 How do you think compliance impacts patient trust in emerging healthcare sectors? Let us know in the comments below.

    • No alternative text description for this image
  • At Releaf, we have built an entire, patient-first ecosystem that simplifies and personalises your healthcare. Reading Charlotte’s post, we couldn’t agree more: up until Releaf’s launch in February 2024, the current UK CBPM landscape had been all over the place. Thankfully - this gave Releaf the opportunity to revolutionise it. So, how does Releaf do this? - Seamless Access for All Patients We understand patients’ previous frustrations: long waiting lists, unclear processes, and overwhelming bureaucracy. That’s why at Releaf, we invested £2M of our own money into our proprietary HealthTech platform - the only UK clinic to demonstrate this. From your virtual consultation through to tracking your prescription delivery, our platform is all-encompassing, allowing patients to access just the care they need. - Affordable, Transparent Pricing At Releaf, we operate with full transparency on pricing, so patients know what to expect upfront, with no hidden costs. That’s why we have a clear pricing page on our website: https://lnkd.in/eudk4aZJ We also have our innovative subscription plan, Releaf+, that gives patients the ability to book unlimited appointments with a consultant at a time that’s convenient for them, all included for just £39.99/month. - Changing the narrative This is essential for Releaf; one of the most powerful ways we do this is by sharing the stories of real patients that highlight the life-changing benefits of medical cannabis. We’re also committed to training our healthcare professionals to confidently prescribe CBPMs, empowering them with data and case studies, led by our COO Graham. - Inclusivity With virtual consultations and medication delivered straight to your door, a Releaf treatment plan is accessible to anyone eligible for it. - Changing the game Our data-driven approach with our PROs (patient reported outcomes), not only personalises patient care but also helps shape a better understanding of cannabis treatments for the wider community. We’re continuously building the perfect ecosystem for our patients and meanwhile transforming medical cannabis access in the UK.

    View profile for Charlotte Caldwell, graphic

    Mother of Billy , the little boy who changed the UK Medical Cannabis Law.

    Welcome to “I Had a Dream” Series - Installment 8 Accessibility: Creating a seamless, patient-centered experience. So, here’s the tea: medical cannabis became legal in the UK in 2018. But for most patients, getting access to it feels like trying to find Narnia in a broom closet. Debilitating conditions? those demand a system that’s simple, stigma free, & dare we dream it? patient-friendly. What’s Holding Things Up? Medical cannabis might be legal, but the road to getting it - potholes, detours, & the occasional bureaucratic sinkhole. • Confusion Central: Patients & some doctors are lost in the weeds (pun intended) when it comes to eligibility & prescriptions. • Red Tape Wrangling: The hoops you have to jump through? Exhausting! • Bank Breaking Prices: Treatment costs can be sky-high. • Stigma-ville: Outdated mindsets still give cannabis the side-eye. • Quality Chaos: Inconsistent products and no-refund policies make trust in the industry shakier than a celeb doing a bush-tucker trial. Mission: Make Prescription Cannabis Actually Work for Patients Here’s what needs to happen to turn this maze into a straight path: 1. Simplify, Simplify, Simplify • One-Stop Shops: Imagine your clinic website where you book appointments, track treatments, track dispensing and get all the info you need. 2. Don’t Make It a Wallet-Wrecker • Subsidies & Insurance: NHS coverage, private insurance inclusion whatever it takes to make treatment affordable. • Compassion Discounts: Special rates for low-income patients because health shouldn’t depend on your bank balance. 3. Bye-Bye Stigma • Public Campaigns: It’s not “stoner culture”- it’s SCIENCE. Let’s reframe the narrative. • Doctor Training: Equip healthcare professionals with the knowledge to talk cannabis like pros. 4. Equity for Everyone • More Access: Expand fit for purpose clinics such as Releaf to every corner of the UK, especially underserved areas. • Inclusive Outreach: Make sure all communities, regardless of background, are in the loop & make cannabis naive patients inclusive. 5. Tech to the Rescue • Telemedicine: Virtual consultations for patients who can’t just pop down to a clinic. • Smart Systems: Use data to fine-tune treatments and improve care. The Dream Scenario Picture this: • Smooth Sailing: No red tape, just a straight shot from consultation to prescription to dispensing. • Affordable Options: Costs that won’t make your wallet cry. • A Strong Support Network: Financial aid, emotional backing, and logistical help all wrapped in a tidy bow. The solution isn’t rocket science - it’s medical science. Every patient deserves care that’s hassle-free, stigma-free, and doesn’t cost a small fortune. So, are you ready to roll up your sleeves & make this happen? Let’s dream big-be different and then make it real. Never.Follow.The.Herd.

    • No alternative text description for this image
  • Last week, our COO, Graham Woodward , sat down with Business of Cannabis | Europe to discuss expanding access to #medicalcannabis training for healthcare professionals in the UK, 6 years on from its legalisation in 2018. When asked about Releaf's approach to onboarding both new patients and new staff, Graham commented: 'There’s often a disparity between the potential patient demographic and the number of doctors available who are equipped to prescribe. While this can be a limiting factor, our proactive recruitment, training programs, and collaborative environment help us address this gap and ensure we’re continually growing our capacity to meet patient needs. We currently handle approximately 100 new patients a day, which is a capacity we deliberately maintain to ensure every patient receives quality care. We’ve scaled our operations to meet this level of demand.' Our success is evident; Releaf's combination of a detailed training and onboarding programme for clinicians, consequent highly trained specialists, lowest patient to support specialist ratio in the sector and £2M proprietary HealthTech platform, allows us handle approximately 100 new patients daily. Though it doesn't stop at 100 patients, we are uniquely positioned to meet the growing demand of the UK's #CBPM sector, all the while maintaining the highest healthcare standards and delivering exceptional patient outcomes. By strategically scaling our operations, our Clinical Team ensures that every patient receives the support they deserve - a testament to our leadership in the evolving CBPM sector. Read the full interview below.

    ICYMI: Business of Cannabis Editor Ben Stevens interviews Graham Woodward RNMH FCMI, COO of Releaf, about the UK's rapidly growing medical cannabis industry. They explore the challenges posed by a shortage of trained cannabis-prescribing doctors, how Releaf addresses this with robust training programs and recruitment, and the importance of real-world data in advancing cannabis research. Woodward also shares details of an exciting collaboration with Leeds University to study cannabis’s effects on long COVID. Could better education and partnerships like this be the key to unlocking the industry's full potential? Find out below 👇 https://lnkd.in/eqkzqmj9

    • No alternative text description for this image

Similar pages

Browse jobs